Navigation Links
Quanterix Receives Funding From the Department of Homeland Security to Develop Test for Botulinum Toxin
Date:12/1/2011

CAMBRIDGE, Mass., Dec. 1, 2011 /PRNewswire/ -- Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array (SiMoA™) technology, announced today that it has been awarded a one year $250,155 contract from the Department of Homeland Security (DHS) to develop an assay capable of detecting single molecules of botulinum toxin (BoNT) within complex environmental samples. In collaboration with the Botulinum Research Center (BRC) at UMass Dartmouth, Quanterix will develop and validate a high sensitivity assay capable of measuring extremely low levels of the BoNT agent. 

"The detection of low copy numbers of toxins and pathogenic bacteria for both clinical and environmental applications requires highly sensitive and rapid detection technologies capable of measuring relevant targets within complex sample mixtures," said David Duffy, Ph.D., Vice President of Research at Quanterix. "The 1,000-fold increase in sensitivity enabled by SiMoA will facilitate the direct detection of the toxins produced by active bacteria at much lower levels than is possible today. As a result, the detection of BoNT protein will provide important functional information on the presence of bacteria that complements nucleic acid identification. We believe that this approach could be extended to other bacteria and applications, for example, hospital acquired infections."

Dr. David Hodge from DHS added, "Quanterix's technology is expected to address a number of challenges currently faced by DHS for identifying active agents of bioterrorism, and offers great promise for a variety of applications in both the private and public sectors."

"Early and accurate detection of botulinum toxin is critical for our national security and public health. The ability to detect extremely low levels of toxin could significantly improve the diagnosis of botulism and better protect humans in biomedical and bio-defense scenarios," said Dr. Bal Ram Singh, BRC Director, and a world leader in the research and detection of botulinum toxin.

About Quanterix

Quanterix Corporation is developing its proprietary Single Molecule Array (SiMoA™) technology for the in vitro diagnostics and life science research markets. The digital nature of SiMoA yields unprecedented assay performance, stemming from a 1,000-fold improvement in sensitivity compared with today's analog only technology. SiMoA will enable researchers in life science to validate novel, low abundance biomolecules from a single droplet of blood, leading to greater insight into disease detection, diagnosis, therapy selection and disease monitoring. Automated systems based on SiMoA will provide diagnostic test information to healthcare practitioners faster, with greater reliability, unprecedented range and increased cost effectiveness.  Founded in 2007, the privately held Cambridge, Massachusetts-based company is backed by leading life science investors including ARCH Venture Partners, Bain Capital Ventures, and Flagship Ventures. For additional information, please visit www.quanterix.com.

About BRC

The Botulinum Research Center (BRC) was established by the University of Massachusetts Dartmouth under the leadership of Dr. Bal Ram Singh, professor of biophysical chemistry. BRC promotes research to create an understanding of the botulinum neurotoxins, their applications and the defenses against such toxins as biothreat agents. BRC was initiated as a national effort, in collaboration with many researchers in academia, government agencies and industry. Currently, it has an international advisory board consisting of scientists from the UK, Japan, Italy, Germany and the US. The state-of-the-art research building was opened on April 5, 2007. This two-story building houses world-class research facilities, including BSL3 labs, for Dr. Singh and for other research activities at UMass Dartmouth.  For more information on BRC, visit www.umassd.edu/brc.


'/>"/>
SOURCE Quanterix Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Quanterix Fifth-Generation PSA Test Enables More Sensitive Measurements Following Surgery
2. Quanterix PSA Test Found to be a Reliable Predictor of Prostate Cancer Recurrence Following Surgery
3. Quanterix Digital ELISA Measures Low Abundance Biomarkers of Inflammation in Crohns Disease
4. Quanterix and STRATEC Announce Strategic Partnership
5. Quanterix Announces Publication of Novel Method Expanding Single Molecule Detection Capability
6. Quanterix Announces New Technology Evaluation Agreement
7. Quanterix Corporation Announces the Addition of Dr. Robert Corn to its Scientific Advisory Board
8. Watsons Generic Yaz(R) Receives FDA Approval
9. UCSB professor receives award for graphene electronics research
10. iBio, Inc. Receives Notice from NYSE Amex Staff that Company Currently is Below Certain Continued Listing Standards
11. Vermillion Receives Notice of Allowance for 5th Biomarker Patent Related to Peripheral Artery Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Calif. , June 23, 2016  Blueprint Bio, ... biological discoveries to the medical community, has closed its ... Matthew Nunez . "We have received ... with the capital we need to meet our current ... essentially provide us the runway to complete validation on ...
(Date:6/23/2016)... June 23, 2016 On Wednesday, June ... 4,833.32, down 0.22%; the Dow Jones Industrial Average edged 0.27% ... at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the ... Nektar Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. ... BIND ). Learn more about these stocks by ...
(Date:6/23/2016)... Prairie, WI (PRWEB) , ... June 23, 2016 ... ... consultancy focused on quality, regulatory and technical consulting, provides a free webinar ... is presented on July 13, 2016 at 12pm CT at no charge. , ...
(Date:6/23/2016)... June 22, 2016  Amgen (NASDAQ: AMGN ... QB3@953 life sciences incubator to accelerate the ... shared laboratory space at QB3@953 was created to help ... obstacle for many early stage organizations - access to ... sponsorship, Amgen launched two "Amgen Golden Ticket" awards, providing ...
Breaking Biology Technology:
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/28/2016)... and BANGALORE, India , April 28, ... Systems, a product subsidiary of Infosys (NYSE: INFY ... announced a global partnership that will provide end ... use mobile banking and payment services.      (Logo: ... key innovation area for financial services, but it also plays ...
(Date:4/26/2016)... and LONDON , April 26, ... of EdgeVerve Systems, a product subsidiary of Infosys ... announced a partnership to integrate the Onegini mobile ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... customers enhanced security to access and transact across ...
Breaking Biology News(10 mins):